Expanding Genomic Testing And AI Will Build Lasting Healthcare Value

Key Takeaways

• Strong growth in testing volumes and biopharma partnerships positions Tempus AI for durable revenue gains, supported by differentiated technology and a growing data advantage.
  
• Expanding clinical-genomic offerings and disciplined cost management drive improving profitability, while rising AI adoption and regulatory clarity provide long-term growth opportunities.
  
• Rising competition, reimbursement uncertainty, regulatory hurdles, and ongoing investment needs threaten Tempus AI's margins, revenue growth, and progress toward sustainable profitability.

Catalysts

Operates as a healthcare technology company.

• Significant volume growth and market share gains in both oncology and hereditary/genetic testing indicate that Tempus AI is leveraging its expanding data repository and technological differentiation to outperform competitors, positioning the company for durable top-line revenue growth.
  
• Tempus AI's large-scale partnerships with biopharma (e.g., AstraZeneca Pathos foundation model) demonstrate rising demand for AI-driven insights amid growing healthcare data complexity, likely driving recurring data licensing revenue and supporting overall earnings stability.
  
• The ongoing expansion of clinical-genomic integrations-such as Tempus' broad MRD and liquid biopsy portfolios-means that, upon future reimbursement, there is further upside to both volume and revenue, with potential positive impact on net margins due to greater operating leverage on fixed R&D costs.
  
• Robust discipline in investment and operating leverage, as evidenced by rapid revenue growth paired with improving adjusted EBITDA and gross margins, supports near-term profitability and strengthens the case for long-term scalable earnings expansion.
  
• Secular increases in the adoption of AI and data analytics in drug development, along with broadening regulatory clarity for digital diagnostics, suggest Tempus AI is uniquely positioned to capture a growing share of healthcare spending, directly increasing revenue and fortifying future margin improvement opportunities.

Tempus AI Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Tempus AI's revenue will grow by 29.8% annually over the next 3 years.
• Analysts are not forecasting that Tempus AI will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Tempus AI's profit margin will increase from -21.0% to the average US Life Sciences industry of 14.2% in 3 years.
• If Tempus AI's profit margin were to converge on the industry average, you could expect earnings to reach $295.1 million (and earnings per share of $1.39) by about August 2028, up from $-199.7 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 61.6x on those 2028 earnings, up from -60.6x today. This future PE is greater than the current PE for the US Life Sciences industry at 29.7x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.27%, as per the Simply Wall St company report.

Tempus AI Future Earnings Per Share Growth

Risks

• Intensifying competition in both the genomics diagnostics and AI data space, including large, well-capitalized incumbents and new entrants, could drive down average selling prices (ASPs) and result in margin compression, impacting Tempus AI's long-term net margins and earnings.
  
• Delays and uncertainty around reimbursement for new assays-particularly in liquid biopsy, MRD (minimal residual disease), and AI-driven diagnostics-may constrain revenue growth and limit the scale-up of higher-margin, innovative offerings.
  
• Escalating regulatory scrutiny and slow progress on clear reimbursement pathways for purely AI-driven algorithms (as noted for non-lab-based insights) could result in under-monetization of Tempus's AI investments, dampening longer-term revenue and free cash flow.
  
• Large pharma clients are still making substantial investments in data and AI, but commentary signals potential vulnerability to market downturns or R&D budget cuts in the biotech/pharma industry, which could impact Tempus AI's recurring revenue from data and insights licensing.
  
• Ongoing requirement for significant R&D and capex investment in infrastructure, foundational models, and product expansion-without corresponding, sustained revenue growth-risks the company outpacing its operating margin improvements and delaying achievement of durable cash flow positivity.

Valuation

• The analysts have a consensus price target of $69.5 for Tempus AI based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $75.0, and the most bearish reporting a price target of just $60.0.
  
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $2.1 billion, earnings will come to $295.1 million, and it would be trading on a PE ratio of 61.6x, assuming you use a discount rate of 7.3%.
  
• Given the current share price of $69.63, the analyst price target of $69.5 is 0.2% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.